ESMO 2021 | Targeted therapies for NSCLC

Robin Cornelissen, MD, PhD, Erasmus University Rotterdam, Rotterdam, Netherlands, discusses targeted therapies for non-small cell lung cancer (NSCLC). Currently, there are several approved drugs targeting frequent mutations in NSCLC. It is necessary to develop drugs targeting less common mutations in genes frequently mutated in NSCLC such as EGFR exon 20 mutations and HER2 exon 20 insertions. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.